CARDIOPROTECTIVE MECHANISMS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

Abstract

Relevance: Type 2 diabetes mellitus (T2DM) significantly increases the risk of ischemic heart disease (IHD). Traditional hypoglycemic therapy often fails to reduce cardiovascular risk, which necessitates the use of drugs with proven cardioprotective effects[1,2].